Fellow Health is a technology company.
Fellow Health has raised $48.0M across 2 funding rounds.
Fellow Health has raised $48.0M in total across 2 funding rounds.
Fellow Health has raised $48.0M in total across 2 funding rounds.
Fellow Health's investors include 5AM Ventures, Alta Partners, Kiersten Stead.
Fellow Health is a technology-enabled company specializing in male reproductive health, offering peer-reviewed, mail-in semen analysis and fertility testing kits that provide clinical-grade results from home.[4][5] It serves patients seeking convenient fertility and post-vasectomy testing as well as healthcare providers like clinics and urologists, solving the problem of archaic, clinic-bound testing methods that lack privacy, speed, and accessibility.[4][5] The company partners with over 1,800 clinical practices, processes 400+ patient samples daily through its CLIA-certified lab, and demonstrates strong growth with 40% year-over-year revenue increase and a path to profitability in its fertility segment by 2026.[4] In July 2025, it closed a $24 million Series B round led by 5AM Ventures, bringing total funding to $48 million.[4]
Fellow Health was founded in 2018 in San Leandro, California, by a team focused on modernizing male reproductive care, with Brian Hogan as CEO.[4] The idea emerged from recognizing the rising demand for male fertility services amid outdated, inconvenient clinic-based testing, aiming to deliver privacy, convenience, and timely results via mail-in kits.[4] Early traction came from securing peer-reviewed validation data—making it the only such mail-in fertility test—and partnerships with top practices like UCSF, where providers report reduced call volumes and high patient satisfaction with fast, detailed results.[4][5] Pivotal funding includes a Series A, follow-on rounds, and the recent Series B from investors like 5AM Ventures, Labcorp Venture Fund, and Genoa Ventures, fueling lab expansion and product scaling.[4]
Fellow Health rides the wave of at-home diagnostics and telehealth personalization, capitalizing on post-pandemic demand for convenient, direct-to-consumer health testing amid rising male infertility awareness (affecting ~40% of couples).[4] Timing aligns with healthcare shifts toward patient empowerment and provider efficiency, as legacy systems strain under volume—Fellow reduces burdens while enabling virtual care scalability.[4][5] Market forces like AI-driven health tech and investor interest in life sciences (e.g., 5AM Ventures' focus on redefining care standards) favor it, positioning Fellow to influence reproductive health norms by standardizing mail-in protocols and partnering with labs like Labcorp.[4] This expands access, particularly for underserved groups, and sets precedents for tech in sensitive diagnostics.
Fellow Health is poised to dominate male reproductive testing with its funding-fueled expansion, targeting broader offerings like additional hormone panels and global reach while hitting fertility profitability in 2026.[4] Trends in personalized at-home health, AI analytics for diagnostics, and value-based care will accelerate its growth, potentially capturing a larger share of the $5B+ fertility market. Its influence may evolve by inspiring similar models in women's health or chronic care, transforming "archaic" testing into seamless standards and delivering universal gains in reproductive access.[1][4] This builds on its core promise: making specialized healthcare easy, affordable, and individualized.
Fellow Health has raised $48.0M across 2 funding rounds. Most recently, it raised $24.0M Series B in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $24.0M Series B | 5AM Ventures, Alta Partners, Kiersten Stead | |
| Jul 1, 2022 | $24.0M Series A | 5AM Ventures, Alta Partners, Kiersten Stead |